Pasquali R, Colella P, Capelli M, Zannarini L, Melchionda N, Barbara L
Panminerva Med. 1989 Jul-Sep;31(3):114-8.
In this study, 16 overweight or obese NIDDM patients with a long period of stable weight and dietary surveillance were treated with 150 mg t.i.d. of Benfluorex per os for 3 months. A significant improvement occurred in the fasting and post-meal glucose levels and in the HbA1C values, regardless of weight changes that occurred throughout the study. No significant changes were found in the fasting or meal-stimulated insulin (IRI) levels and in the glucose:IRI molar ratios. On the contrary, there were no significant variations in C-peptide levels while the glucose:CPR ratio appeared to decrease while on Benfluorex. In basal conditions, 11 patients presented insulin insensitivity (as measured by the glucose-insulin-somatostatin technique) which was unaffected by the pharmacological treatment. Benfluorex may therefore ameliorate metabolic control in overweight or obese NIDDM patients, but our data do not clarify whether its effects are mediated by an improvement in the action of insulin in peripheral tissues.
在本研究中，16名体重长期稳定且接受饮食监测的超重或肥胖型非胰岛素依赖型糖尿病（NIDDM）患者口服苯氟雷司，每次150毫克，每日三次，持续治疗3个月。无论在整个研究过程中体重有无变化，空腹及餐后血糖水平以及糖化血红蛋白（HbA1C）值均有显著改善。空腹或餐后刺激胰岛素（IRI）水平以及血糖：IRI摩尔比未发现显著变化。相反，C肽水平无显著变化，而在服用苯氟雷司期间，血糖：CPR比值似乎有所下降。在基础状态下，11名患者存在胰岛素抵抗（通过葡萄糖-胰岛素-生长抑素技术测定），药物治疗对此无影响。因此，苯氟雷司可能改善超重或肥胖型NIDDM患者的代谢控制，但我们的数据并未阐明其作用是否通过改善外周组织中胰岛素的作用来介导。
